Atlanta nonprofit caring for families while battling childhood cancer
But CURE Childhood Cancer isn't only thinking about the child fighting the disease, they're also looking out for the families fighting alongside them.
For 50 years, they have been working to advance research and treatment for cancers affecting children.
While survival rates are above 80%, cancer is still the leading cause of death by disease for children.
[DOWNLOAD: Free WSB-TV News app for alerts as news breaks]
Channel 2′s Karyn Greer spoke with the mother of a childhood cancer survivor who said CURE supported her and her family.
'I remember looking over at my daughter, who was 15 at the time, and I just looked at her. We locked eyes and I was like, 'Do you understand what the doctor just said?' You know, we're, you know, tears and just stunned and shock and surreal,' Karen Rutherford said of the moment she learned her daughter had cancer.
Rutherford says she was determined to get through her daughter Katie's diagnosis of rabdomysacoma, a rare solid cancerous tumor on her face.
'We were referred to Emory and they finally were able to do a biopsy. But it probably was a four month period of not really knowing, and it looked like it was growing before our eyes. Every day, this little, tiny little finally got to the size of like a quarter before we figured out what was going on,' she remembered.
That's when Rutherford says they were introduced to CURE.
'When you have a child in cancer, you don't want to leave their room, so to be able to just hop down to the family room real quick and grab a sandwich and come right back and be with my daughter, that was huge,' she said.
Mark Myers with CURE Childhood Cancer says there are between 500 and 600 children in Georgia diagnosed with cancer each year.
'An overwhelming majority are treated in Atlanta,' Myers said.
TRENDING STORIES:
Atlanta bagpiper killed while scuba diving; son who vanished 4 years ago found dead at home
Federal agents raid manufacturing plant in Bartow County in labor trafficking investigation
4 Georgia soldiers have died after being reported missing in Lithuania
On Wednesday, donating to CURE Childhood Cancer and raising money for cancer research was as easy as grabbing a bite to eat.
All of the proceeds from all purchases at Jersey Mike's Subs' locations in metro Atlanta, Columbus, Athens and Macon are going directly to CURE Childhood Cancer.
Channel 2 Action News stopped by a restaurant in Atlanta and found it packed with supporters.
'It's been huge,' manager Travis Joyner said. 'Customers coming in, one of our biggest days for a good cause.'
Last year's Day of Giving resulted in CURE receiving more than $500,000 for emergency financial assistance.
[SIGN UP: WSB-TV Daily Headlines Newsletter]
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
4 days ago
- Medscape
Cilta-cel CAR T: Myeloma ‘Cure' and Conjecture
Not a day goes by in clinic without a patient asking about the recent New York Times article on multiple myeloma: "Doc, is there really a cure now? I want this treatment." The article was boldly titled "From No Hope to a Potential Cure for a Deadly Blood Cancer." But did we truly leap from "no hope" to "potential cure"? In this commentary, I explore what the article got right, where caution is warranted, and how I think about the notion of a cure for myeloma. Manni Mohyuddin, MD Historically, patients with heavily pretreated, relapsed myeloma had grim prognoses, often with less than a year of survival. The arrival of BCMA- and GPRC5D-directed therapies has rewritten expectations for this population. Cilta-cel, a BCMA-targeted chimeric antigen receptor (CAR) T-cell product, is a standout. A recent long-term follow-up study in Journal of Clinical Oncology (JCO) reported that one third (32 of 97) of patients remained progression-free 5 years after a single cilta-cel infusion. It's a remarkable outcome, one worthy of celebration, yet we must interpret these results with care. Of the 113 enrolled patients, only 97 received cilta-cel, and only the outcomes of those 97 are described, with the unfortunate ones whose disease progressed before cilta-cel infusion omitted from this narrative. Patients with rapidly progressing or unstable disease often don't make it to CAR T — a natural selection bias. Moreover, heavy censoring at the tail end of the Kaplan-Meier survival curve, a statistical method used to track patient outcomes over time, and where many patients drop out or are lost to follow-up, introduces uncertainty about what the results will be with even longer follow-up. A real-world study of cilta-cel showed 12-month progression-free survival (PFS) at just 68%, making it unlikely that we will see such outcomes with 5 years of follow-up in the real world, and highlighting the gap between clinical trial efficacy and real-world effectiveness. This discrepancy is not new. The MAIA study reported a median PFS beyond 5 years for newly diagnosed patients treated with daratumumab, lenalidomide, and dexamethasone (DRd). Yet, in real-world cohorts, PFS is closer to 2-3 years. Differences in censoring, progression definitions, and patient selection drive this gap. Given these dynamics, a 30% five-year PFS in real-world practice for this patient population seems unlikely. While some patients, perhaps 10%-15%, may experience truly durable responses, presenting the trial's cure fraction as broadly achievable would be misleading. The word "cure" featured prominently in both the JCO publication and the New York Times article. However, the most recent definition of cure in myeloma includes sustained measurable residual disease (MRD) negativity off all therapy for at least 5 years. When asked, patients have clearly indicated that they do not consider themselves cured while still on treatment (as is often the case in myeloma), no matter what the disease response is. I celebrate this trial for many reasons, but one important one is that it gave patients such valuable time off from treatment. However, during long-term follow-up of this trial, MRD negativity was not routinely assessed. At one center, 12 patients were evaluated serially and found to be MRD negative. But this was a post hoc analysis, and data from other centers weren't reported. Given the nuanced ways that relapse is defined in myeloma (with markers having to be above a certain threshold), we must be cautious in declaring these patients cured. Some of them may already have signs of relapse that has not yet reached a certain threshold to call it as progression. I also must admit to feeling distressed that a top-notch journal allowed the authors to make such bold statements based on post hoc analysis from a single center. Such post hoc data mining — where researchers look for patterns after seeing the results — carries a high risk for false discoveries and should not support definitive claims about cure. The article implies that these long-term remissions and cure are unprecedented. That's simply not true. Long-term follow-up from studies using intensive upfront therapy have shown that many patients — especially those with standard-risk disease — achieve long remissions, are off treatment, and remain alive for years. To claim that we've gone from "no hope" to "potential cure" neglects this important context. Myeloma had seen sustained, incremental progress across multiple drug classes well before cilta-cel emerged. Cilta-cel is a powerful therapy, but it is not without risk — something the article omits. It has horrendous, unpredictable toxicities that were not mentioned in the New York Times article. These include secondary cancers, a horrible diarrhea due to immune-mediated gut damage, and often irreversible neurologic damage. Thankfully, these are not experienced by the majority of patients, but we are imperfect at predicting to whom they do happen, and many of these toxicities are currently permanent. Despite these critiques, I view the New York Times story as a net positive. It raises awareness about the progress we've made and offers patients hope. I do believe we are curing some patients with myeloma, and cilta-cel is part of that story. However, the 30% cure rate cited in the article is probably an illusion among such a heavily pretreated population (although I am hopeful for an even higher cure rate in the newly diagnosed setting). I envision a future with safer therapies that more reliably increase the cure fraction. And while I appreciate how this article shined a spotlight on myeloma, I hope that future media coverage embraces the nuance that this disease — and its patients — deserve.
Yahoo
17-06-2025
- Yahoo
'New pathway' to cure for HIV discovered using tech from COVID-19 vaccine
Researchers have taken a giant leap in the search for an HIV cure by discovering a way to identify the virus even as it is camouflaged among other cells. HIV spreads by invading and multiplying within white blood cells, which fight disease and infection. One of the main roadblocks in developing a cure has been finding a way to isolate and kill the virus without also killing white blood cells and harming the body's immune system. Researchers from the Peter Doherty Institute for Infection and Immunity in Melbourne, Australia have now cultivated a method to identify the virus among white blood cells, as demonstrated in a recent paper published in Nature Communications, isolating the virus for potential treatment. The technology involves mRNA — molecules isolated from DNA that can teach the body how to make a specific protein — which were also used in the COVID-19 vaccines. By introducing mRNA to white blood cells, it can force the cells to reveal the virus. Using mRNA in this way was 'previously thought impossible,' research fellow at the Doherty Institute and co-first author of the study Paula Cevaal told The Guardian, but the new development "could be a new pathway to an HIV cure.' 'In the field of biomedicine, many things eventually don't make it into the clinic – that is the unfortunate truth; I don't want to paint a prettier picture than what is the reality,' Cevaal said. 'But in terms of specifically the field of HIV cure, we have never seen anything close to as good as what we are seeing, in terms of how well we are able to reveal this virus. A cure is still years away, as Cevaal said it would still need to be tested on animals and then humans to see if it can be done safely on living beings before they can test whether or not a potential treatment would even work. However, she added that that "we're very hopeful that we are also able to see this type of response in an animal, and that we could eventually do this in humans.'
Yahoo
16-06-2025
- Yahoo
Georgia is one of the worst places to age in place, study says
A study suggests that Georgia is one of the least desirable states to age in place. The population of those 65 and older keeps growing, and the vast majority of them want to stay in their homes rather than retire in assisted living or retirement communities. Seniorly, a provider of an online senior living directory and other resources, studied data in 10 categories to compare all 50 states and the District of Columbia. [DOWNLOAD: Free WSB-TV News app for alerts as news breaks] These categories include seniors' risk of isolation, home health care quality, home health aide availability, emergency care timeliness, smart home adoption, housing costs, road safety, local walkability, food delivery access and weather hazards. The best states supported seniors in their desire to stay put, making it easier to get around, stay healthy and feel supported. According to Seniorly, Georgia is not one of those states. The Peach State ranked no. 48, behind Alabama and ahead of North Carolina. Kentucky ranks second to last. Georgia struggles with meal delivery for seniors, 'providing services to only 957 per 100,000 older adults under the Older Americans Act,' Seniorly said. Here's how Georgia ranked in various aspects of senior care, according to Seniorly: Seniors who live alone: 40.5% (Rank: 11) Home health agencies with a 4.5 or 5-star rating: 17.5% (Rank: 16) Seniors per home health or personal care aide: 37 (Rank: 46) Median wait time between ER arrival and departure: 161 minutes (Rank: 33 (tie)) Population who interact with household equipment via the internet: 25.7% (Rank: 27) Homeowners ages 65+ who spend more than 30% of their income on housing: 25.1% (Rank: 29) Seniors involved in fatal car crashes: 20.7 per 100,000 drivers (Rank: 38) Average walk score across the largest cities: 26 (Rank: 43 (tie)) Home-delivered meals via Older Americans Act Title 3: 957 per 100,000 seniors (Rank: 50) Average annual precipitation: 49.9 inches (Rank: 41) Florida, despite its sizable retirement community, ranks last in the study primarily because of its limited availability of home health aides, how much of their salaries seniors spend on housing and weather hazards. Ranking first for aging in place is Utah. Seniorly said seniors there face the lowest risks of social isolation and among the lowest risks of precipitation. Utah seniors also lead the nation in the use of smart home technology, devices that Seniorly suggests can help older adults stay independent longer. The other states in the top five are North Dakota, New Jersey, Idaho and Texas. Seniorly also said that no state is perfect, with some vast differences in the state between different aspects of senior care. For instance, Mississippi ranks 45 for aging in place, but ranks third for quality of home health agencies. A record 4.2 million Americans will turn 65 this year, and according to the latest AARP survey, 75% of older Americans say they want to remain in their homes and communities as they get older, rather than move to assisted living or retirement facilities. TRENDING STORIES: Man sentenced for fatally shooting victim, blinding another during 'heinous robbery' in Gwinnett GSP chase, crash shuts down intersection in downtown Atlanta Xpress bus service routes discontinued, park-and-ride lots closed [SIGN UP: WSB-TV Daily Headlines Newsletter]
